Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "EBITDA-margin"

144 News Found

IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr
News | August 12, 2022

IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr

The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal


Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%
News | August 10, 2022

Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%

EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%


Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
News | August 08, 2022

Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%

Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore


Biocon - Generics & research grow; biosimilar stagnates - ICICI Securities
News | May 26, 2022

Biocon - Generics & research grow; biosimilar stagnates - ICICI Securities

ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E


Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
News | May 12, 2022

Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up

Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins


Ajanta Pharma - Stellar show in its branded generics: Anand Rathi
News | May 12, 2022

Ajanta Pharma - Stellar show in its branded generics: Anand Rathi

With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24


Bayer posts higher sales, profit in first quarter
News | May 11, 2022

Bayer posts higher sales, profit in first quarter

Company's net income rose by 57.5 percent to 3.291 billion euros in Q1


Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY
News | May 10, 2022

Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY

The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt


Beta Drugs announces oultook for FY 22-23
News | April 28, 2022

Beta Drugs announces oultook for FY 22-23

The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years


Syngene full-year revenue from operations up 19% to Rs. 2604 crore
News | April 27, 2022

Syngene full-year revenue from operations up 19% to Rs. 2604 crore

Revenue from operations up 15% to Rs. 758 crore in fourth quarter